Zusammenfassung
Der transmembranöse HER-2-Rezeptor ist ein 185 kD schweres Protein, welches von dem
Protoonkogen HER-2 auf dem langen Arm des Chromosoms 17 (17 q 12 - 21) kodiert wird.
Bei etwa einem Drittel aller Mammakarzinome wird das HER-2-Protein überexprimiert.
Eine wichtige Vorbedingung für den Einsatz der monoklonalen Antikörpertherapie mit
Trastuzumab (Herceptin®) ist die Bestimmung des HER-2-Status. Verschiedene Testverfahren
auf der Protein- (Immunhistochemie [IHC], Enzyme-linked Immunosorbent Assay [ELISA]
und Western Blot) und auf der Genebene (Fluoreszenz-in-situ-Hybridisierung [FISH],
chromogene In-situ-Hybridisierung [CISH], Polymerase-Ketten-Reaktion [PCR] und Southern
Blot) stehen dafür zur Verfügung. Am häufigsten werden zurzeit die IHC und die FISH
verwendet. Eine Kombination dieser beiden Verfahren wird zur Routinetestung empfohlen.
Zunächst sollte die HER-2-Expression immunhistologisch untersucht werden. Fälle mit
dem HercepTest-Score 2 + sollten dann mittels FISH nachuntersucht werden. Für die
Zukunft stellt die CISH möglicherweise eine interessante Alternative zur FISH-Technik
dar. Chromogene ersetzen bei dieser Methode Fluoreszenzfarbstoffe. CISH ermöglicht
so die Verwendung von Lichtmikroskopen und Archivierung von Schnittpräparaten. Die
quantitative ELISA-Bestimmung des abgespaltenen extrazellulären Anteils (ECD) des
HER-2-Proteins im Patientenserum als Surrogatmarker für das Tumorvolumen stellt aus
klinischer Sicht eine besonders interessante Zukunftsperspektive dar. Mit ihr könnte
die Effektivität adjuvanter Therapien bzw. das Auftreten von Rezidiven frühzeitig
festgestellt werden. Jedoch sollten zur endgültigen klinischen Validierung der CISH
und des ELISA als Methoden der HER-2-Testung weitere prospektive Studien mit größeren
Patientenzahlen folgen.
Abstract
The transmembrane HER-2 receptor is 185 kD of molecular weight and is encoded by the
proto oncogene HER-2 on the long arm of chromosome 17 (17 q 12 - 21). Over-expression
of HER-2 is found in about one third of all breast carcinomas. Determining the HER-2
status is a prerequisite for the use of the monoclonal antibody trastuzumab (Herceptin™)
in the therapy of metastatic breast cancer. Various test assays for HER-2 either on
the protein level (immunhistochemistry [IHC], enzyme-linked immunosorbent assay [ELISA],
western blot) or on the gene level (fluorescence in situ hybridization [FISH], chromogenic in situ hybridization [CISH], polymerase chain reaction [PCR], and southern blot) are available.
However, IHC and FISH are most often applied. For routine HER-2 testing a combination
of both methods is recommended. IHC should be used for screening, followed by FISH
only in those cases scored as 2 + by the HercepTest. In future, CISH may represent
a useful alternative to FISH. In CISH fluorescent dyes are replaced by chromogenes,
facilitating the use of light microscopes and the filing of slides. Quantitative analysis
of the shed extracellular domain of HER-2 (HER-2 ECD) in the patients' serum by ELISA
is helpful for clinical use. With HER-2 ECD as a surrogate marker of the tumor volume
monitoring of adjuvant therapies and tumor recurrence would be feasible. However,
more prospective studies with higher numbers of patients are required for validation
of these new methods.
Schlüsselwörter
CISH - ELISA - FISH - HER-2 - Immunhistochemie - Mammakarzinom - PCR
Key words
Breast cancer - CISH - ELISA - FISH - HER-2 - immunohistochemistry - PCR
Literatur
- 1
Ahr A, Holtrich U, Karn T, Solbach C, Gätje R, Scharl A, Strebhardt K, Kaufmann M.
Detektion differentiell exprimierter Gene beim primären Mammakarzinom mittels cDNA-Array-Hybridisierung.
Geburtsh Frauenheilk.
2000;
60
412-417
- 2
Allred D, Swanson P.
Testing for erbB-2 by immunohistochemistry in breast cancer.
Am J Clin Pathol.
2000;
113
171-175
- 3
Biechle I, Olivi M, Champeme M, Vidaud D, Lidereau R, Vidaud M.
Novel approach to quantitative polymerase chain reaction using real-time detection:
application to the detection of gene amplification in breast cancer.
Int J Cancer.
1998;
78
661-666
- 4
Bilous M, Dowsett M, Hanna W, Isola J, Lebeau A, Moreno A, Penault-Llorca F, Rüschoff J,
Tomasic G, van de Vijver M.
Current perspectives on HER2 testing: a review of national testing guidelines.
Mod Pathol.
2003;
16
173-182
- 5
Busmanis I, Feleppa F, Jones A, McGrath K, Reed R, Collins J, Russell I, Begley C.
Analysis of cerbB2 expression using a panel of 6 commercially avaiable antibodies.
Pathology.
1994;
26
261-267
- 6
Carlomagno C, Perrone F, Gallo C, De Laurentiis M, Lauria R, Morabito A, Pettinato G,
Panico L, D'Antonio A, Bianco A, De Placido S.
c-erbB-2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage
breast cancer without axillary lymph node metastases.
J Clin Oncol.
1996;
14
2702-2708
- 7
Cobley M, Vogel C, Tripathy D, Robert N, Scholl S, Fehrenbacher L, Wolter J, Paton V,
Shak S, Lieberman G, Slamon D.
Multinational study of the efficacy and safety of humanized anti-HER-2 monoclonal
antibody in women who have HER-2 overexpressing metastatic breast cancer that has
progressed after chemotherapy for metastatic disease.
J Clin Oncol.
1999;
17
2639-2648
- 8
Codony-Servat J, Albanell J, Lopez-Talavera J, Arribas J, Baselga J.
Cleavage of the HER2 ectodomain is a pervanadate-activable process that is inhibited
by the tissue inhibitor of metalloproteinases-1 in breast cancer cells.
Cancer Res.
1999;
59
1196-1201
- 9
Coussens L, Yang-Fen T, Liao Y, Chen E, Gray A, McGrath J, Seeburg P, Libermann T,
Schlessinger J, Francke U, Levinson A, Ullrich A.
Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal
location with neu oncogene.
Science.
1985;
230
1132-1139
- 10
Couturier J, Vincent-Salomon A, Nicolas A, Beuzeboc P, Mouret E, Zafrani B, Sastre-Garau X.
Strong correlation between results of fluorescence in situ hybridization and immunohistochemistry
of the ERBB2 (HER-2/neu) gene status in breast carcinoma.
Mod Pathol.
2000;
13
1238-1243
- 11
Dandachi N, Dietze O, Hauser-Kronberger C.
Chromogenic in situ hybridization: a novel approach to a practical and sensitive method
for the detection of HER2 oncogene in archival human breast carcinoma.
Lab Invest.
2002;
82
1007-1014
- 12
Deng G, Kim Y.
Quantification of erbB-2 gene copy number in breast cancer by an improved polymerase
chain reaction (PCR) technique, competitively differential PCR.
Breast Cancer Res Treat.
1999;
58
213-217
- 13
Dowsett M, Cooke T, Ellis I, Gullick W, Gusterson B, Mallon E, Walker R.
Assessment of HER-2 status in breast cancer: why, when and how?.
Eur J Cancer.
2000;
36
170-176
- 14
Ellis I, Dowsett M, Bartlett J, Walker R, Cooke T, Gullick W, Gusterson W, Mallon E,
Barrett Lee P.
Recommendations for HER2 testing in the UK.
J Clin Pathol.
2000;
53
890-892
- 15
Ellis M, Coop A, Singh B, Mauriac L, Llombert-Cussac A, Jänicke F, Miller W, Evans D,
Dugan M, Brady C, Quebe-Fehling F, Borgs M.
Letozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1
and/or ErbB-2 positive, estrogen receptor-positive primary breast cancer: evidence
from a phase III radomized trial.
J Clin Oncol.
2001;
19
3808-3816
- 16
Gramlich T, Cohen C, Fritsch C, DeRose P, Gansler T.
Evaluation of c-erbB-2 amplification in breast carcinoma by differential polymerase
chain reaction.
Am J Clin Pathol.
1994;
101
493-494
- 17
Gupta D, Middleton L, Whitaker M, Abrams J.
Comparison of fluorescence and chromogenic in situ hybridization for detection of
HER-2/neu oncogene in breast cancer.
Am J Clin Pathol.
2003;
119
381-387
- 18
Gusterson B, Gelber R, Goldhirsch A, Price K, Save-Soderborgh J, Anbazhagan R, Styles J,
Rudenstam C, Golouh R, Reed R, Martinez-Tello F, Tiltman A, Torhorst J, Grigolato P,
Betelheim R, Neville A, Burki K, Castiglione M, Collins J, Lindtner J, Senn H-J. for
the International (Ludwig) Breast Cancer Study Group .
Prognostic importance of c-erbB-2 expression in breast cancer.
J Clin Oncol.
1992;
10
1049-1056
- 19
Hait N.
The prognostic and predictive values of ECD-HER-2.
Clin Cancer Res.
2001;
7
2601-2604
- 20
Hanna W.
Testing for HER-2 status.
Oncology.
2001;
61 (Suppl 2)
22-30
- 21
Horton J.
Trastuzumab use in breast cancer: clinical issues.
Cancer Control.
2002;
9
499-507
- 22
Hung M, Lau Y.
Basic science of HER-2/neu: a review.
Semin Oncol.
1999;
26
51-59
- 23
Huober J, Wagner U, Wallwiener D.
Der Stellenwert von Aromatasehemmern der dritten Generation in der endokrinen Therapie
des Mammakarzinoms - Zeit zum Umdenken?.
Geburtsh Frauenheilk.
2002;
62
15-21
- 24
Jacobs T, Gown A, Yaziji H, Barnes M, Schnitt S.
Comparison of fluorescence in situ hybridization and immunohistochemistry for the
evaluation of HER-2/neu in breast cancer.
J Clin Oncol.
1999;
17
1974-1982
- 25
Jacobs T, Prileau J, Stillman I, Schmitt S.
Loss of tumor marker-immunostaining intensity on stored paraffin slides of breast
cancer.
J Natl Cancer Inst.
1996;
88
1054-1059
- 26
Konecny G, Pegram M, Untch M, Thomssen C, Jänicke F, Hepp H, Slamon D.
HER-2/neu als prädiktiver Faktor beim Mammakarzinom.
Geburtsh Frauenheilk.
2000;
60
609-619
- 27
Königshoff M, Wilhelm J, Bohle R M, Pingoud A, Hahn M.
HER-2/neu gene copy number quantified by real-time PCR: comparison of gene amplification,
heterozygosity, and immunohistochemical status in breast cancer tissue.
Clin Chem.
2003;
49
219-229
- 28
Kumamoto H, Sasano H, Taniguchi T, Suzuki T, Moriya T, Ichinohasama R.
Chromogenic in situ hybridization analysis of HER-2/neu status in breast carcinoma:
application in screening of patients for trastuzumab (Herceptin) therapy.
Path Int.
2001;
51
579-584
- 29
Langton B C, Crenshaw M C, Chao L A, Stuart S G, Akita R W, Jackson J E.
An antigen immunologically related to the external domain of gp185 is shed from nude
mouse tumors overexpressing the c-erbB-2 (HER-2/neu) oncogene.
Cancer Res.
1991;
51
2593-2598
- 30
Lehmann U, Glockner S, Kleeberger W, von Wasielewski H, Kreipe H.
Detection of gene amplification in archival breast cancer specimens by laser-assisted
microdissection and quantitative real-time polymerase chain reaction.
Am J Pathol.
2000;
156
1855-1864
- 31
Muss H, Thor A, Berry D.
c-erbB-2 expression and response to adjuvant therapy in women with node-positive early
breast cancer.
N Engl J Med.
1994;
330
1260-1266
- 32
Nacht M, Ferguson A, Zhang W, Petroziello J, Cook B, Gao Y, Maguire S, Riley D, Coppola G,
Landes G, Madden S, Sukumar S.
Combining serial analysis of gene expression and array technologies to identify genes
differentially expressed in breast cancer.
Cancer Res.
1999;
59
5464-5470
- 33
Pauletti G, Godolphin W, Press M, Slamon D.
Detection and quantification of HER-2/neu gene amplification in human breast cancer
archival material using flourescence in situ hybridization.
Oncogene.
1996;
13
63-72
- 34
Pietras R, Arboleda J, Reese D, Wongvipat N, Pegram M, Ramos L, Gorman C, Parker M,
Sliwkowski M, Slamon D.
HER2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent
growth in human breast cancer cells.
Oncogene.
1995;
10
2435-2446
- 35
Press M, Hung G, Godolphin W, Slamon D.
Sensitivity of HER-2/neu antibodies in archival tissue samples: Potential source of
error in immunohistochemical studies of oncogene expression.
Cancer Res.
1994;
54
2771-2777
- 36
Pupa S, Menard S, Morelli D, Pozzi B, De Palo G, Colnaghi M.
The extracellular domain of the c-erbB-2 oncoprotein is released from tumor cells
by proteolytic cleavage.
Oncogene.
1993;
8
2917-2923
- 37
Quenel N, Wafflart J, Bonichon F, de Mascarel, Trojani M, Durand M, Avril A, Coindre J.
The prognostic value of c-erB-2 in primary breast carcinomas: a study on 942 cases.
Breast Cancer Res Treat.
1995;
35
283-291
- 38
Rosen P, Lesser M, Arroyo C, Cranor M, Borgen P, Norton L.
Immunohistochemical detection of HER-2/neu in patients with axillary lymph node negative
breast carcinoma. A study of epidemiologic risk factors, histologic features, and
prognosis.
Cancer.
1995;
75
1320-1326
- 39
Ross J S, Fletcher J A.
The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and
target for therapy.
Stem Cells.
1998;
16
413-428
- 40
Ross J, Fletcher J.
HER-2/neu (c-erb-B2) gene and protein in breast cancer.
Am J Clin Pathol.
1999;
112 (Suppl 1)
S53-S67
- 41
Schaller G.
Metastasiertes Mammakarzinom: Welche Patienten profitieren von einer Antikörpertherapie?.
Dtsch Ärzteblatt.
2001;
98
A3014-A3015
- 42
Schnitt S, Jacobs T.
Current status of HER2 testing: Between a rock and a hard place.
Am J Clin Pathol.
2001;
116
806-810
- 43
Slamon D, Clark G, Wong S, Levin W, Ullrich A, McGuire W.
Human breast cancer: correlation of relapse and survival with amplification of HER-2/neu
oncogene.
Science.
1987;
235
177-182
- 44
Specht K, Richter T, Muller U, Walch A, Werner M, Hofler H.
Quantitative gene expression analysis in microdissected archival formalin-fixed and
paraffin-embedded tumor tissue.
Am J Pathol.
2001;
158
419-429
- 45
Stearns V, Yamauchi H, Hayes D.
Circulating tumor markers in breast cancer: accepted utilities and novel prospects.
Brest Cancer Res Treat.
1998;
52
239-259
- 46
Tanner M, Gancberg D, di Leo A, Larsimont D, Rouas G, Piccart M, Isola J.
Chromogenic in situ hybridization: A practical alternative for fluorescence in situ
hybridization to detect HER2/neu oncogene amplification in archival breast cancer
samples.
Am J Pathol.
2000;
157
1467-1472
- 47
Tanner M, Järvinen P, Isola J.
Amplification of HER-2/neu and topoisomerase II alpha in primary and metastatic breast
cancer.
Cancer Res.
2001;
61
5345-5348
- 48
Tetu B, Brisson J.
Prognostic significance of HER-2/neu oncoprotein expression in node-positive breast
cancer.
Cancer.
1994;
73
2359-2365
- 49
Tsuda H, Akiyama F, Terasaki H, Hasegawa T, Kurosumi M, Shimadzu M, Yamamori S, Sakamoto G.
Detection of HER-2/neu (c-erbB-2) DNA amplification in primary breast cancer.
Cancer.
2001;
92
2965-2974
- 50
Tsuda H, Sasano H, Akiyama F, Kurosumi M, Hasegawa T, Osamura R, Sakamoto G.
Evaluation of interobserver agreement in scoring immunohistochemical results of HER-2/neu
(c-erbB-2) expression detected by HercepTest, Nichirei polyclonal antibody, CB11 and
TA250 in breast carcinoma.
Path Int.
2002;
52
126-134
- 51
Tubbs R, Pettay J, Roche P, Stoler M, Jenkins R, Grogan T.
Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy:
apparent immunohistochemical false-positives do not get the message.
J Clin Oncol.
2001;
19
2714-2721
- 52
Untch M, Ditsch N, Hermelink K.
Immuntherapy: new options in breast cancer treatment.
Expert Rev Anticancer Ther.
2003;
3
403-408
- 53
van de Vijver M.
Assessment of the need and appropriat method for testing for the human epidermal growth
factor receptor-2 (HER2).
Eur J Cancer.
2001;
37
S11-S17
- 54
van de Vijver M.
Emerging technology for HER2 testing.
Oncology.
2002;
63 (Suppl 1)
33-38
- 55
van Diest P, van Dam P, Henzen-Logmans S, Berns E, van der Burg M, Green J, Vergote I.
A scoring system for immunohistochemical staining: consensus report of the task force
for basic research of the EORTC-GCCG. European Organisation for Research and Treatment
of Cancer Gynaecological Cancer Co-operative Group.
J Clin Pathol.
1997;
50
801-804
- 56
Vennstrom B, Bishop J.
Isolation and characterization of chicken DNA homologous to the two putative oncogenes
of avian erythroblastosis virus.
Cell.
1982;
28
135-143
- 57
Vincent-Salomon A, Jouve M, Genin P, Freneaux P, Sigal-Zafrani B, Caly M, Beuzeboc P,
Pouillart P, Saestre-Garaux X.
HER-2 status in patients with breast carcinoma is not modified selectively by preoperative
chemotherapy and is stable during the metastatic process.
Cancer.
2002;
94
2169-2173
- 58
Wang S, Saboorian M, Frenkel E, Haley B, Siddiqui M, Gokaslan S, Wians F J, Hyan L,
Ashfaq R.
HER-2/neu status in breast cancer: Automated cellular imaging system (ACIS)-assisted
quantification of immunohistochemical assay achieved high accuracy in comparison with
fluorescence in situ hybridization assay as the standard.
Am J Clin Pathol.
2001;
116
495-503
- 59
Yamauchi H, Stearns V, Hayes D F.
When is a tumor marker ready for prime time? A case study of c-erbB-2 as a predictive
factor in breast cancer.
J Clin Oncol.
2001;
19
2334-2356
- 60
Youngson B, Anelli A, Van Zee K, Borgen P, Norton L, Rosen P.
Microdissection and molecular genetic analysis of HER-2/neu in breast carcinoma.
Am J Surg Pathol.
1995;
19
1354-1368
- 61
Zhao J, Wu R, Au A, Marquez A, Yu Y, Shi Z.
Determination of HER2 gene amplification by chromogenic in situ hybridization (CISH)
in archival breast carcinoma.
Mod Pathol.
2002;
15
657-665
Dr. med. Frank Noack
Institut für Pathologie, Universitätsklinikum Schleswig-Holstein, Campus Lübeck
Ratzeburger Allee 160
23538 Lübeck
eMail: noack@patho.mu-luebeck.de